Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560842 | 0.89 | CTSL (0.45) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11637675 | 0.89 | CTSL (0.45) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11635684 | 0.89 | CTSL (0.45) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11632428 | 0.85 | NAAA (0.42) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11633899 | 0.85 | SLC18A3 (0.48) | NAAASLC18A3 | |
| SCHEMBL11632425 | 0.85 | NAAA (0.42) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11634473 | 0.85 | MEN1 (0.42) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL16600197 | 0.85 | FABP7 (0.40) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11634478 | 0.85 | MEN1 (0.42) | MEN1CYP2C19KMT2ACTSLCTSB | |
| SCHEMBL11633902 | 0.85 | SLC18A3 (0.48) | NAAASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-2975022-B1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | FUJIFILM TOYAMA CHEMICAL CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-9862676-B2 | Hydroxamic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975022-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2016-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039751-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE OR SALT THEREOF | H1-0, H1-2, HDAC1 | APP 4735/4885MEN1 1824/4885CYP2C19 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.